WEST Earnings|Guidance|Buyback|Dividend Thursday, July 23, 2026 +0.50 Positive

West Pharmaceutical Q2 2026 Results Beat Expectations, Raises Guidance

West Pharmaceutical Services reported strong financial results for the second quarter of 2026, exceeding expectations due to robust sales growth in proprietary products. The company raised its full-year revenue and adjusted EPS guidance.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day